Compare GSK plc (GSK) vs IAC/Interactivecorp (PPLI) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

PPLI trades at $45.30, down 1.29% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported negative earnings in recent quarters, missing estimates, with Q2 2026 results pending. Revenue declined to $2.39B in 2025, though net loss narrowed to $104M. Analyst consensus is bullish with a $55.40 price target, and MGM Resorts is reportedly in acquisition talks.

Outlook: Potential upside exists from acquisition interest and analyst targets, but risks include consecutive earnings misses, revenue decline, and negative cash flow. Investors should weigh M&A prospects against fundamental weaknesses and high debt levels before considering a position.